Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

anbenitamab (KN026)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Alphamab, CSPC Pharma

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

mobocertinib (12)

trastuzumab-dttb (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	Gastrointestinal Cancer	HER-2 positive	Gastrointestinal Cancer	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 expression	Gastroesophageal Junction Adenocarcinoma	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2
HER-2 underexpression	Solid Tumor	HER-2 underexpression	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	KN026 Sensitive: C3 – Early Trials KN026 Sensitive : C3	KN026 Sensitive: C3 – Early Trials KN026 Sensitive : C3